Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AEMDBullishM&Anews

High materiality8/10

Aethlon Merges with North Immunology to form Nasdaq-listed NRTX with $180M funding

Sep 17, 2026, 10:15 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Surge in AEMD stock on all-stock merger news; higher liquidity potential and new funding could attract speculators, though dilution risk tempers upside.

AI summary

What happened, with direct paths to the underlying reporting

Aethlon Medical announces an all-stock merger with North Immunology, creating a combined company to trade as NRTX on Nasdaq Capital Market. A $180 million private placement backs the deal, supporting NOR-101 development and Hemopurifier monetization through contingent rights. Close is targeted for Q1 2027, subject to approvals; the deal pledges substantial equity value and a clear pipeline plan, but triggers meaningful dilution for existing AEMD holders.

Aethlon Medical signs all-stock merger with North Immunology. Combined pro forma equity ~ $346.5M.
Pre-merger AEMD holders ~4.75% ownership; North Immunology ~95.25% ownership post-merger.
$180M private placement funds support operations through 2H 2028.
NOR-101 lead candidate to start Phase 1a in 2027; topline data in 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.